- Home
- BMEZ vs PHAT Comparison
BMEZ vs PHAT Comparison
Compare BMEZ & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMEZ | PHAT |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.9M | 894.0M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BMEZ | PHAT |
|---|---|---|
| Price | $14.62 | $13.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 226.2K | ★ 958.0K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $13.40 | $2.21 |
| 52 Week High | $15.80 | $18.31 |
Technical Indicators
Market Signals| Indicator | BMEZ | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 68.54 |
| Support Level | $13.78 | $13.02 |
| Resistance Level | $15.23 | $14.37 |
| Average True Range (ATR) | 0.23 | 0.59 |
| MACD | 0.07 | 0.23 |
| Stochastic Oscillator | 77.99 | 99.17 |
Price Performance
Historical ComparisonAbout BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Term Trust is a closed-end fund focused on the healthcare and health sciences sector. Its investment objectives are to provide total return and income through long-term capital appreciation.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.